ATLAS News · Companies

Moderna Lifts 2026 Growth Outlook, Holds Back 2027 Guidance

Published November 15, 2026 · 4 sources

Moderna raised its 2026 revenue growth outlook to 15%-25% but withheld 2027 guidance, cut Ares borrowing costs and extended a $1.5 billion facility to 2031.

What happened

Moderna raised its 2026 revenue growth outlook to a range of 15%-25% but did not provide guidance for 2027, according to ad-hoc-news.de. The outlet also links the company's legal chief departure to the wait for a 2027 forecast.

Separately, ad-hoc-news.de reports that Moderna trimmed the cost of its drawn credit by 75 basis points and extended a $1.5 billion facility to 2031. The facility is described as being with Ares.

The outlet also reports on a melanoma result for Moderna and says spending plans are running ahead of revenue. It notes a November 18 conference that follows the 15%-25% outlook.

Context

Companies often update annual revenue expectations alongside financing changes, and investors typically watch for forward guidance to judge the next year's plans.

Why it matters

The raised 2026 outlook combined with missing 2027 guidance and a leadership change may keep attention on how Moderna plans its finances and revenue going forward.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

ModernaMRNA

−3.45%

Healthcare · NASDAQ

Live price

$223.37

live price · USD

Latest close before this story: $223.37−3.45% vs. previous close ($231.35) · November 13
Chance of a rise in 1 month: 44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $179.06 and $257.14; 9 in 10, between $129.92 and $354.41.

See the full ATLAS analysis of Moderna →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Moderna's Legal Chief Exit Adds a Governance Note to the 2027 Forecast Wait · ad-hoc-news.de · November 15, 2026
Moderna Cuts Ares Borrowing Cost by 75 Basis Points While Investors Await a 2027 Revenue Roadmap · ad-hoc-news.de · November 15, 2026
Moderna's Melanoma Win Is Only Half the Story as Spending Plans Outrun Revenue · ad-hoc-news.de · November 15, 2026
Moderna stock: November 18 conference follows 15%-25% outlook · ad-hoc-news.de · November 15, 2026

Latest market news · Markets today on ATLAS · Moderna

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer